Heron Therapeutics is trading at $0.36, down 5.02% in after-hours trading, with no clear company-specific announcement or late-breaking catalyst identified for the October 7 decline.
- The company’s recent licensing agreement and prior-quarter results are earlier developments, not a confirmed explanation for the move.
- The regular session moved sharply higher while major U.S. indexes finished modestly lower; this mixed context does not establish a cause.
- After-hours volume information was not available in the provided price context.